Skip to main content
. Author manuscript; available in PMC: 2010 May 18.
Published in final edited form as: Vaccine. 2009 Apr 3;27(23):3045–3052. doi: 10.1016/j.vaccine.2009.03.026

Table 1.

RSV Neutralizing Antibody in FI-RSV-Immunized Mice

TLR Agonist Log2(reciprocal dilution 60%)
At Priming At Challenge Day -1 Sera Day 42 Sera
PBS PBS 2.73 ± 0.81 8.23 ± 1.56
CpG PBS 5.62 ± 1.92a 9.87 ± 0.58
TLR7/8c PBS 3.59 ± 1.53 9.02 ± 0.73
CpG + TLR7/8 c PBS 7.85 ± 0.02 a 8.33 ± 1.56
PBS CpG NT b 7.24 ± 2.44
PBS TLR7/8 c NT b 8.34 ± 0.96
PBS CpG + TLR7/8 c NT b 8.93 ± 0.80
a

Statistically significant difference relative to PBS-treated group, p<0.05. N=10 in two separate experiments.

b

NT=not tested

c

Two separate experiments were performed, one using the TLR7/8 agonist R-848 and one with TLR7/8 agonist 3M-012. Results were similar between the 2 experiments.